Herlev, Denmark

Brian Lauritzen

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2013-2017

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Brian Lauritzen

Introduction

Brian Lauritzen is a notable inventor based in Herlev, Denmark. He has made significant contributions to the field of medical science, particularly in the development of antibodies that target specific pathways in the body. With a total of three patents to his name, Lauritzen's work has the potential to impact the treatment of coagulopathies.

Latest Patents

One of Lauritzen's latest patents involves antibodies against tissue factor pathway inhibitor (TFPI). This invention relates to antibodies that specifically bind to TFPI and reduce the clotting time of blood. Such antibodies are particularly useful in treating subjects with coagulopathy. Another patent focuses on methods of treating coagulopathies using these antibodies against TFPI, further emphasizing the therapeutic potential of his innovations.

Career Highlights

Brian Lauritzen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to explore and develop groundbreaking solutions in the medical field. His dedication to innovation is evident in his research and patent filings.

Collaborations

Lauritzen collaborates with talented professionals in his field, including Ida Hilden and Berit Olsen Krogh. These collaborations enhance the research environment and contribute to the advancement of medical technologies.

Conclusion

Brian Lauritzen's contributions to the field of medical science through his patents and collaborations highlight his role as an influential inventor. His work has the potential to significantly improve treatments for coagulopathies, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…